Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes Academic Article uri icon

Overview

MeSH Major

  • Antimetabolites, Antineoplastic
  • DNA Methylation
  • Myelodysplastic Syndromes
  • Neoplasms, Second Primary

abstract

  • We retrospectively assessed morphologic and cytogenetic responses to 5-azacytidine and decitabine in a cohort of 42 adult therapy-related myelodysplastic syndromes (tMDS) patients treated at Memorial Sloan-Kettering Cancer Center and in 2 industry-sponsored decitabine trials (D0007 and DACO-020). The overall response rate (complete remission+marrow CR+hematologic improvement) was 38%, including 6 patients with complete remission (14%), 6 with marrow CR with or without hematologic improvement (14%), and 4 with hematologic improvement alone (10%). We conclude that DNA methyltransferase inhibitors showed activity in tMDS that is roughly comparable to that seen in de novo MDS.

publication date

  • September 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.leukres.2012.04.025

PubMed ID

  • 22608310

Additional Document Info

start page

  • 1093

end page

  • 7

volume

  • 36

number

  • 9